The Orally Bioavailable MDM2 Antagonist RG7112 and Pegylated Interferon α 2a Target JAK2V617F-positive Progenitor and Stem Cells

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2014 May 30

PMID 24869939

Citations 38

Authors

Min Lu

Lijuan Xia

Yan Li

Xiaoli Wang

Ronald Hoffman

Affiliations

Soon will be listed here.

Abstract

The Philadelphia chromosomal-negative chronic myeloproliferative neoplasms (MPNs) originate at the level of the hematopoietic stem cell (HSC). The protracted clinical course of the MPNs has limited the use of potentially toxic treatment modalities, which may eliminate the responsible malignant clone. Treatment with low doses of RG7112, an orally available small-molecule inhibitor of p53-MDM2, both alone and combined with pegylated interferon α 2a (Peg-IFNα 2a), significantly decreased MPN colony-forming unit-granulocyte macrophage and burst-forming unit-erythroid numbers and preferentially eliminated the total number of JAKV617F(+) MPN hematopoietic progenitor cells. The effects of RG7112 and Peg-IFNα 2a on MPN progenitor cells were dependent on blocking p53-MDM2 interactions and activating the p53 pathway, thereby increasing MPN CD34(+) cell apoptosis. Treatment of polycythemia vera (PV) and primary myelofibrosis (PMF) CD34(+) cells with low doses of RG7112 and Peg-IFNα 2a before their transplantation into immune-deficient mice decreased the degree of donor-derived chimerism as well as the JAK2V617F allele burden, indicating that these drugs can each alone or in combination deplete MPN HSCs. These results provide a rationale for the use of combinations of low doses of RG7112 and Peg-IFNα 2a for the treatment of PV or PMF patients with the intent of altering their natural history.

Citing Articles

Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms.

Gou P, Liu D, Ganesan S, Lauret E, Maslah N, Parietti V Blood Cancer J. 2024; 14(1):1.

PMID: 38177095 PMC: 10766605. DOI: 10.1038/s41408-023-00969-6.

Recent advances in therapies for primary myelofibrosis.

Vainchenker W, Yahmi N, Havelange V, Marty C, Plo I, Constantinescu S Fac Rev. 2023; 12:23.

PMID: 37771602 PMC: 10523375. DOI: 10.12703/r/12-23.

Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges.

Ajufo H, Waksal J, Mascarenhas J, Rampal R Ther Adv Hematol. 2023; 14:20406207231177282.

PMID: 37564898 PMC: 10410182. DOI: 10.1177/20406207231177282.

MDM2 Inhibition in the Treatment of Glioblastoma: From Concept to Clinical Investigation.

Pellot Ortiz K, Rechberger J, Nonnenbroich L, Daniels D, Sarkaria J Biomedicines. 2023; 11(7).

PMID: 37509518 PMC: 10377337. DOI: 10.3390/biomedicines11071879.

Always stressed but never exhausted: how stem cells in myeloid neoplasms avoid extinction in inflammatory conditions.

Zhao H, Deininger M Blood. 2023; 141(23):2797-2812.

PMID: 36947811 PMC: 10315634. DOI: 10.1182/blood.2022017152.

References

Silver R, Vandris K, Goldman J . Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. Blood. 2011; 117(24):6669-72. DOI: 10.1182/blood-2010-11-320069. View

Quintas-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie A . Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013; 122(6):893-901. PMC: 3739035. DOI: 10.1182/blood-2012-07-442012. View

Mullally A, Bruedigam C, Poveromo L, Heidel F, Purdon A, Vu T . Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood. 2013; 121(18):3692-702. PMC: 3643767. DOI: 10.1182/blood-2012-05-432989. View

Mesa R . Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders. Int J Hematol. 2002; 76 Suppl 2:193-203. DOI: 10.1007/BF03165117. View

Vassilev L, Vu B, Graves B, Carvajal D, Podlaski F, Filipovic Z . In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-8. DOI: 10.1126/science.1092472. View

Hernandez-Boussard T, Montesano R, Hainaut P . IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer. Hum Mutat. 1999; 14(1):1-8. DOI: 10.1002/(SICI)1098-1004(1999)14:1<1::AID-HUMU1>3.0.CO;2-H. View

Ishii T, Bruno E, Hoffman R, Xu M . Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood. 2006; 108(9):3128-34. DOI: 10.1182/blood-2006-04-017392. View

Hasselbalch H . A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol. 2011; 4(6):637-55. DOI: 10.1586/ehm.11.63. View

Li Y, Matsumori H, Nakayama Y, Osaki M, Kojima H, Kurimasa A . SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis. Genes Cells. 2010; 16(1):34-45. DOI: 10.1111/j.1365-2443.2010.01460.x. View

10.

Harutyunyan A, Klampfl T, Cazzola M, Kralovics R . p53 lesions in leukemic transformation. N Engl J Med. 2011; 364(5):488-90. DOI: 10.1056/NEJMc1012718. View

11.

Lu M, Zhang W, Li Y, Berenzon D, Wang X, Wang J . Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol. 2010; 38(6):472-80. PMC: 4293703. DOI: 10.1016/j.exphem.2010.03.005. View

12.

Gabler K, Behrmann I, Haan C . JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms. JAKSTAT. 2013; 2(3):e25025. PMC: 3772115. DOI: 10.4161/jkst.25025. View

13.

Tsurumi S, Nakamura Y, Maki K, Omine M, Fujita K, Okamura T . N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders. Am J Hematol. 2002; 71(2):131-3. DOI: 10.1002/ajh.10188. View

14.

Lu M, Wang J, Li Y, Berenzon D, Wang X, Mascarenhas J . Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells. Blood. 2010; 116(20):4284-7. PMC: 2993627. DOI: 10.1182/blood-2010-04-279125. View

15.

Nii T, Marumoto T, Tani K . Roles of p53 in various biological aspects of hematopoietic stem cells. J Biomed Biotechnol. 2012; 2012:903435. PMC: 3388322. DOI: 10.1155/2012/903435. View

16.

Marine J . MDM2 and MDMX in cancer and development. Curr Top Dev Biol. 2011; 94:45-75. DOI: 10.1016/B978-0-12-380916-2.00003-6. View

17.

Spivak J . Polycythemia vera: myths, mechanisms, and management. Blood. 2002; 100(13):4272-90. DOI: 10.1182/blood-2001-12-0349. View

18.

Gowin K, Mesa R . Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis. Expert Opin Investig Drugs. 2013; 22(12):1603-11. DOI: 10.1517/13543784.2013.832199. View

19.

Kiladjian J, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M . Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008; 112(8):3065-72. DOI: 10.1182/blood-2008-03-143537. View

20.

Townsend P, Scarabelli T, Davidson S, Knight R, Latchman D, Stephanou A . STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem. 2003; 279(7):5811-20. DOI: 10.1074/jbc.M302637200. View